Precigen (NASDAQ:PGEN) COO Sells 32,739 Shares

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 32,739 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $6.86, for a total transaction of $224,589.54. Following the transaction, the chief operating officer directly owned 465,012 shares of the company’s stock, valued at approximately $3,189,982.32. This trade represents a 6.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Precigen Trading Up 4.6%

Shares of PGEN traded up $0.32 during trading on Friday, reaching $7.23. 5,754,727 shares of the company traded hands, compared to its average volume of 4,614,801. The stock has a 50-day simple moving average of $5.17 and a 200-day simple moving average of $4.48. The stock has a market cap of $2.58 billion, a PE ratio of -6.95 and a beta of 1.02. Precigen, Inc. has a twelve month low of $1.70 and a twelve month high of $7.26. The company has a quick ratio of 4.12, a current ratio of 4.58 and a debt-to-equity ratio of 2.15.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. The firm had revenue of $54.98 million for the quarter, compared to analyst estimates of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. Precigen’s quarterly revenue was up 6322.7% on a year-over-year basis. On average, analysts anticipate that Precigen, Inc. will post -0.02 earnings per share for the current year.

Hedge Funds Weigh In On Precigen

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming acquired a new position in shares of Precigen during the first quarter worth about $27,000. NBC Securities Inc. purchased a new position in Precigen in the fourth quarter worth approximately $38,000. Mason Investment Advisory Services Inc. purchased a new position in Precigen in the fourth quarter worth approximately $42,000. Abel Hall LLC acquired a new position in Precigen during the 4th quarter worth approximately $44,000. Finally, Royal Bank of Canada increased its position in shares of Precigen by 102.6% in the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

Wall Street Analysts Forecast Growth

PGEN has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Citizens Jmp increased their target price on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. HC Wainwright raised their target price on Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.50.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.